Skip to main content
Top
Published in: Journal of Diabetes & Metabolic Disorders 1/2017

Open Access 01-12-2017 | Research article

Cardiovascular risk assessment by FRS and SCORE in Iranian adult population

Authors: Alipasha Meysamie, Fereshteh Salarvand, MirHojjat Khorasanizadeh, Reza Ghalehtaki, Mahsa Eskian, Saeed Ghodsi, Shirin Ghalehtaki, Mehrshad Abbasi, Koroush Etemad, Fereshteh Asgari, Alireza Esteghamati

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2017

Login to get access

Abstract

Background

Handling the growing epidemic of coronary heart disease in developing nations hinges on primary prevention, which logistically requires directing preventive interventions to those at the highest risk. Therefore, implementing cardiovascular risk assessment profiles is crucial to distinguish high risk groups who truly need extensive preventive measures. We aimed to draw a picture of the cardiovascular risk profiles in the Iranian adult population for the first time.

Methods

Demographic, anthropometric, and laboratory data as well as blood pressure and smoking status of 3944 subjects participating in the 2011 national surveillance of risk factors for non-communicable diseases were used to calculate the mean estimated risk of coronary artery disease and the relative frequency of low-, medium- and high-risk subjects based on FRS and SCORE indices in general population as well as different age, sex, and residence subgroups.

Results

The average 10-year risk of coronary artery disease (FRS) and 10-year risk of fatal coronary and cerebrovascular accidents (SCORE) in the 25 to 64 year-old population was 13.82 and 0.72 respectively. The relative frequency of the intermediate- and high- risk subjects was 25.8 and 22.6% based on FRS and 9.2 and 1.8% based on SCORE respectively. Average FRS and SCORE were significantly higher among men than women, but were not significantly different among urban and rural residents.

Conclusions

A significant proportion of the Iranian population, based on FRS model, will be at moderate to high risk of coronary events in the next 10 years. Urgent preventive plans are needed at the national level.
Literature
2.
go back to reference Talaei M, Sarrafzadegan N, Sadeghi M, Oveisgharan S, Marshall T, Thomas GN, et al. Incidence of cardiovascular diseases in an Iranian population: the Isfahan cohort study. Arch Iran Med. 2013;16(3):138–44.PubMed Talaei M, Sarrafzadegan N, Sadeghi M, Oveisgharan S, Marshall T, Thomas GN, et al. Incidence of cardiovascular diseases in an Iranian population: the Isfahan cohort study. Arch Iran Med. 2013;16(3):138–44.PubMed
3.
go back to reference Hatmi ZN, Tahvildari S, Gafarzadeh Motlag A, Sabouri KA. Prevalence of coronary artery disease risk factors in Iran: a population based survey. BMC Cardiovasc Disord. 2007;7:32.CrossRefPubMedPubMedCentral Hatmi ZN, Tahvildari S, Gafarzadeh Motlag A, Sabouri KA. Prevalence of coronary artery disease risk factors in Iran: a population based survey. BMC Cardiovasc Disord. 2007;7:32.CrossRefPubMedPubMedCentral
4.
go back to reference Sepanlou SG, Kamangar F, Poustchi H, Malekzadeh R. Reducing the burden of chronic diseases: a neglected agenda in Iranian health care system, requiring a plan for action. Arch Iran Med. 2010;13(4):340–50.PubMed Sepanlou SG, Kamangar F, Poustchi H, Malekzadeh R. Reducing the burden of chronic diseases: a neglected agenda in Iranian health care system, requiring a plan for action. Arch Iran Med. 2010;13(4):340–50.PubMed
5.
go back to reference Hadaegh F, Harati H, Ghanbarian A, Azizi F. Prevalence of coronary heart disease among Tehran adults: Tehran lipid and glucose study. East Mediterr Health J. 2009;15(1):157–66.PubMed Hadaegh F, Harati H, Ghanbarian A, Azizi F. Prevalence of coronary heart disease among Tehran adults: Tehran lipid and glucose study. East Mediterr Health J. 2009;15(1):157–66.PubMed
6.
go back to reference Capewell S, Ford ES, Croft JB, Critchley JA, Greenlund KJ, Labarthe DR. Cardiovascular risk factor trends and potential for reducing coronary heart disease mortality in the United States of America. Bull World Health Organ. 2010;88(2):120–30.CrossRefPubMed Capewell S, Ford ES, Croft JB, Critchley JA, Greenlund KJ, Labarthe DR. Cardiovascular risk factor trends and potential for reducing coronary heart disease mortality in the United States of America. Bull World Health Organ. 2010;88(2):120–30.CrossRefPubMed
7.
go back to reference Kamboj L, Oh P, Levine M, Kammila S, Casey W, Harterre D, et al. Cost effectiveness of a systematic guidelines-based approach to the prevention and management of vascular disease in a primary care setting. Int J Cardiol. 2016;203:893–9.CrossRefPubMed Kamboj L, Oh P, Levine M, Kammila S, Casey W, Harterre D, et al. Cost effectiveness of a systematic guidelines-based approach to the prevention and management of vascular disease in a primary care setting. Int J Cardiol. 2016;203:893–9.CrossRefPubMed
8.
go back to reference Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987–1003.CrossRefPubMed Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987–1003.CrossRefPubMed
9.
go back to reference Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham risk score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005;165(22):2644–50.CrossRef Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham risk score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005;165(22):2644–50.CrossRef
10.
go back to reference Noshad S, Abbasi M, Etemad K, Meysamie A, Afarideh M, Khajeh E, et al. Prevalence of metabolic syndrome in Iran: a 2011 update. J Diabetes. 2017;9(5):518–25. Noshad S, Abbasi M, Etemad K, Meysamie A, Afarideh M, Khajeh E, et al. Prevalence of metabolic syndrome in Iran: a 2011 update. J Diabetes. 2017;9(5):518–25.
11.
go back to reference D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation. 2008;117(6):743–53.CrossRefPubMed D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation. 2008;117(6):743–53.CrossRefPubMed
12.
go back to reference Bozorgmanesh M, Hadaegh F, Azizi F. Predictive accuracy of the 'Framingham's general CVD algorithm' in a middle eastern population: Tehran lipid and glucose study. Int J Clin Pract. 2011;65(3):264–73.CrossRefPubMed Bozorgmanesh M, Hadaegh F, Azizi F. Predictive accuracy of the 'Framingham's general CVD algorithm' in a middle eastern population: Tehran lipid and glucose study. Int J Clin Pract. 2011;65(3):264–73.CrossRefPubMed
13.
go back to reference Khalili D, Hadaegh F, Soori H, Steyerberg EW, Bozorgmanesh M, Azizi F. Clinical usefulness of the Framingham cardiovascular risk profile beyond its statistical performance: the Tehran lipid and glucose study. Am J Epidemiol. 2012;176(3):177–86.CrossRefPubMed Khalili D, Hadaegh F, Soori H, Steyerberg EW, Bozorgmanesh M, Azizi F. Clinical usefulness of the Framingham cardiovascular risk profile beyond its statistical performance: the Tehran lipid and glucose study. Am J Epidemiol. 2012;176(3):177–86.CrossRefPubMed
14.
go back to reference Eshtiaghi R, Esteghamati A, Nakhjavani M. Menopause is an independent predictor of metabolic syndrome in Iranian women. Maturitas. 2010;65(3):262–6.CrossRefPubMed Eshtiaghi R, Esteghamati A, Nakhjavani M. Menopause is an independent predictor of metabolic syndrome in Iranian women. Maturitas. 2010;65(3):262–6.CrossRefPubMed
15.
go back to reference Nematy M, Alinezhad-Namaghi M, Rashed MM, Mozhdehifard M, Sajjadi SS, Akhlaghi S, et al. Effects of Ramadan fasting on cardiovascular risk factors: a prospective observational study. Nutr J. 2012;11:69.CrossRefPubMedPubMedCentral Nematy M, Alinezhad-Namaghi M, Rashed MM, Mozhdehifard M, Sajjadi SS, Akhlaghi S, et al. Effects of Ramadan fasting on cardiovascular risk factors: a prospective observational study. Nutr J. 2012;11:69.CrossRefPubMedPubMedCentral
16.
go back to reference Ford ES, Giles WH, Mokdad AH. The distribution of 10-year risk for coronary heart disease among US adults: findings from the National Health and nutrition examination survey III. J Am Coll Cardiol. 2004;43(10):1791–6.CrossRefPubMed Ford ES, Giles WH, Mokdad AH. The distribution of 10-year risk for coronary heart disease among US adults: findings from the National Health and nutrition examination survey III. J Am Coll Cardiol. 2004;43(10):1791–6.CrossRefPubMed
17.
go back to reference Dent TH. Predicting the risk of coronary heart disease I. The use of conventional risk markers. Atherosclerosis. 2010;213(2):345–51.CrossRefPubMed Dent TH. Predicting the risk of coronary heart disease I. The use of conventional risk markers. Atherosclerosis. 2010;213(2):345–51.CrossRefPubMed
18.
go back to reference Brindle P, Beswick A, Fahey T, Ebrahim S. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart. 2006;92(12):1752–9.CrossRefPubMedPubMedCentral Brindle P, Beswick A, Fahey T, Ebrahim S. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart. 2006;92(12):1752–9.CrossRefPubMedPubMedCentral
19.
go back to reference Chia YC, Gray SY, Ching SM, Lim HM, Chinna K. Validation of the Framingham general cardiovascular risk score in a multiethnic Asian population: a retrospective cohort study. BMJ Open. 2015;5(5):e007324.CrossRefPubMedPubMedCentral Chia YC, Gray SY, Ching SM, Lim HM, Chinna K. Validation of the Framingham general cardiovascular risk score in a multiethnic Asian population: a retrospective cohort study. BMJ Open. 2015;5(5):e007324.CrossRefPubMedPubMedCentral
20.
go back to reference Barroso LC, Muro EC, Herrera ND, Ochoa GF, Hueros JI, Buitrago F. Performance of the Framingham and SCORE cardiovascular risk prediction functions in a non-diabetic population of a Spanish health care centre: a validation study. Scand J Prim Health Care. 2010;28(4):242–8.CrossRefPubMedPubMedCentral Barroso LC, Muro EC, Herrera ND, Ochoa GF, Hueros JI, Buitrago F. Performance of the Framingham and SCORE cardiovascular risk prediction functions in a non-diabetic population of a Spanish health care centre: a validation study. Scand J Prim Health Care. 2010;28(4):242–8.CrossRefPubMedPubMedCentral
21.
go back to reference van der Heijden AA, Ortegon MM, Niessen LW, Nijpels G, Dekker JM. Prediction of coronary heart disease risk in a general, pre-diabetic, and diabetic population during 10 years of follow-up: accuracy of the Framingham, SCORE, and UKPDS risk functions: the Hoorn study. Diabetes Care. 2009;32(11):2094–8.CrossRefPubMedPubMedCentral van der Heijden AA, Ortegon MM, Niessen LW, Nijpels G, Dekker JM. Prediction of coronary heart disease risk in a general, pre-diabetic, and diabetic population during 10 years of follow-up: accuracy of the Framingham, SCORE, and UKPDS risk functions: the Hoorn study. Diabetes Care. 2009;32(11):2094–8.CrossRefPubMedPubMedCentral
22.
go back to reference Crouse JR 3rd, Bots ML, Evans GW, Palmer MK, O'Leary DH, Grobbee DE, et al. Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study. Eur J Cardiovasc Prev Rehabil. 2010;17(2):223–9.CrossRefPubMed Crouse JR 3rd, Bots ML, Evans GW, Palmer MK, O'Leary DH, Grobbee DE, et al. Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study. Eur J Cardiovasc Prev Rehabil. 2010;17(2):223–9.CrossRefPubMed
23.
go back to reference Esteghamati A, Meysamie A, Khalilzadeh O, Rashidi A, Haghazali M, Asgari F, et al. Third national surveillance of risk factors of non-communicable diseases (SuRFNCD-2007) in Iran: methods and results on prevalence of diabetes, hypertension, obesity, central obesity, and dyslipidemia. BMC Public Health. 2009;9:167.CrossRefPubMedPubMedCentral Esteghamati A, Meysamie A, Khalilzadeh O, Rashidi A, Haghazali M, Asgari F, et al. Third national surveillance of risk factors of non-communicable diseases (SuRFNCD-2007) in Iran: methods and results on prevalence of diabetes, hypertension, obesity, central obesity, and dyslipidemia. BMC Public Health. 2009;9:167.CrossRefPubMedPubMedCentral
24.
go back to reference Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. JAMA. 1990;264(23):3018–24. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. JAMA. 1990;264(23):3018–24.
25.
go back to reference Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, et al. Lipoprotein-associated phospholipase a(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet (London, England). 2010;375(9725):1536–44.CrossRef Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, et al. Lipoprotein-associated phospholipase a(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet (London, England). 2010;375(9725):1536–44.CrossRef
Metadata
Title
Cardiovascular risk assessment by FRS and SCORE in Iranian adult population
Authors
Alipasha Meysamie
Fereshteh Salarvand
MirHojjat Khorasanizadeh
Reza Ghalehtaki
Mahsa Eskian
Saeed Ghodsi
Shirin Ghalehtaki
Mehrshad Abbasi
Koroush Etemad
Fereshteh Asgari
Alireza Esteghamati
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Diabetes & Metabolic Disorders / Issue 1/2017
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1186/s40200-017-0316-4

Other articles of this Issue 1/2017

Journal of Diabetes & Metabolic Disorders 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine